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Oropharyngeal candidiasis continues to be considered the most common opportunistic disease in Aids patients.
This study was designed to investigate species distribution, serotype and antifungal susceptibility profile among
Candida spp. isolated from the oral cavity of Aids patients recruited from six Brazilian university centers. Oral swabs
from 130 Aids patients were plated onto CHROMagar Candida medium and 142 isolates were recovered. Yeast
isolates were identified by classical methods and serotyped using the Candida Check system-Iatron. Antifungal
susceptibility testing was performed according to the NCCLS microbroth assay. C. albicans was the most frequently
isolated species (91%), and 70% of the isolates belonged to serotype A. We detected 12 episodes of co-infection
(9%), including co-infection with both serotypes of  C. albicans. Non-albicans species were isolated from 12 epi-
sodes, 50% of them exhibited DDS or resistance to azoles. Otherwise, only 8 out 130 isolates of  C. albicans exhibited
DDS or resistance to azoles. Brazilian Aids patients are infected mainly by C. albicans serotype A, most of them
susceptible to all antifungal drugs.
Key words: oral candidiasis - Candida spp. - Aids - Brazil
Oropharyngeal candidiasis (OPC) is the most common
opportunistic infection observed in Aids patients, occur-
ring in an estimated 80 to 95% of these patients, when the
CD4 T-lymphocyte counts are below 200 cells/mm3 (Crowe
et al. 1991, Dupont et al. 1994, Calvet et al. 1997). Increased
retroviral replication and an associated decline in immune
defenses render these patients particularly susceptible to
OPC, to the extent that it is consider an early sign of HIV
infection (Darouiche 1998). The prolonged nature of Aids
predisposes these patients to recurrent episodes of OPC
that can increase in frequency and severity with progres-
sive HIV disease. Therefore, the prolonged management
of OPC in this patient population causes the develop-
ment of drug-resistant candidiasis (Powderly et al. 1999).
Candida resistance to the azoles has been frequently at-
tributed to a selective pressure caused by the use of these
antifungal drugs as OPC prophylaxis or treatment
(Barchiesi et al. 1996, Dronda et al. 1996). Many studies
have estimated the incidence of clinical fluconazole resis-
tance to be from 6 to 36%, depending on the patient group
studied and the case definition used (Baily et al. 1994,
Chavanet et al. 1994, Johnson et al. 1995).
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The advent of highly active antiretroviral therapy
(HAART) has permitted suppression of viral replication to
very low levels and a partial recovery of CD4 T cell count in
HIV infected patients. Consequently, the incidence of op-
portunistic infections has declined, changing the natural
history of HIV infection. However, opportunistic infections
remain a problem among patients with a delayed diagnosis
of infection and among non-responders to HAART (Brodt
et al. 1997, Palella et al. 1998, Patton et al. 2000).
The aims of this study were to determine the species
distribution and C. albicans serotypes of yeast isolates
from Brazilian Aids patients with OPC and to analyze the
in vitro susceptibility pattern of the isolates against
fluconazole, itraconazole and ketoconazole.
MATERIALS AND METHODS
Specimen collection and culture of clinical isolates -
We conducted a prospective study over a 24-month pe-
riod, from March 1998 to February 2000, aimed at the in-
vestigation of species distribution, serotype and antifun-
gal susceptibility profile among Candida spp. isolated
from the oral cavity of Aids patients. Six tertiary care medi-
cal centers with active HIV patient treatment clinics joined
the project at different stages during the two year study
period: Universidade Federal de São Paulo, Unifesp,
Universidade Federal do Rio Grande do Norte,
Universidade de São Paulo, Ribeirão Preto, Universidade
Federal do Paraná, Universidade Federal da Bahia and
Universidade Federal de Uberlândia. The centers were
requested to send sequential samples isolated from the
oral cavity of Aids patients.
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Samples were obtained by swabbing the oral mucosa
of the subjects with sterile cotton swabs, plated onto
CHROMagar Candida® (CHOMagar Microbiology, Paris,
France) and incubated at 30oC for a period not exceeding
five days.  After primary isolation, colonies were subcul-
tured on Sabouraud dextrose agar (SDA, Difco Laborato-
ries, Detroit). The centers were requested to send the iso-
lates recovered to the reference laboratory, at Unifesp,
together with case report forms containing clinical and
epidemiological information, including data about the use
of HAART and CD4 cells count for each patient at the
time of collection.
Only one sampling was taken from each patient with
OPC. When more than one Candida species were iso-
lated from oral cavity of the same patient, all isolates were
identified.
Green colonies isolated on CHROMagar Candida®
were presumptively identified as C. albicans and the iden-
tification was confirmed by chlamydoconidia production
on cornmeal-Tween 80 agar. Colonies presenting other
colours were subcultured on new Sabouraud-dextrose agar
plates and were identified according to a standard method.
Briefly, isolates were submitted to microscopic morphol-
ogy observation on cornmeal-Tween 80 agar, and carbo-
hydrate fermentation and assimilation of 7 and 15 sugars,
respectively. If necessary, organisms were also checked
for urease production, nitrate assimilation, and ascospore
formation (Kurtzman & Fell 1998).
Serotyping assay - Strains of C. albicans were pre-
pared for slide agglutination serotyping with serodiag-
nostic reagent number 6 from Candida Check kit (Iatron
Laboratories, Inc., Higashi-Kanda, Chiyoda, Tokio, Japan),
as suggested in the package insert. C. albicans cultures
were incubated on Sabouraud-dextrose agar plates for 48
h at 25oC. Small amounts of specimen yeast cells was
inoculated onto a Candida Check test tray and approxi-
mately 0.05 ml of specific serum (number 6) was added for
testing and physiological saline was added as control.
The glass test tray was stirred for about 1-2 min. A posi-
tive agglutination reaction was interpreted by the visual-
ization of aggregates considered to be indicative of C.
albicans serotype A. Negative results in the agglutina-
tion reaction with reagent number 6 were considered to
be indicative of C. albicans serotype B.
Antifungal susceptibility testing - Susceptibility to
azole drugs was tested using the broth microdilution
method recommended by the National Committee for Clini-
cal Laboratory Standards (NCCLS 1997). Reference grade
powders of fluconazole (Pfizer Inc., New York, NY, USA),
itraconazole (Janssen Pharmaceutica, Titusville, NJ, USA)
and ketoconazole (Janssen Pharmaceutica) were used to
obtain final drug concentration ranging from 0.125 to 64
µg/ml, 0.03 to 16 µg/ml and 0.03 to 16 µg/ml respectively.
Briefly, broth microdilution testing was performed in ster-
ile, flat-bottom 96-well microplates (Nunclon, Delta, Nunc.
InterMed, Denmark), with RPMI-1640 (American
Biorganics, Niagara Falls, NY, USA) added with L-
glutamine and without bicarbonate, and buffered with
MOPS, pH 7.0. The microplates containing double the
final concentration of azoles were prepared in advance
and stored at
-70oC for no more than three weeks until use. On the day
of testing, the turbidity of the inoculum suspension was
adjusted by the spectrophotometer to that produced by a
0.5 McFarland standard at 530 nm wavelength. A volume
of 100 µl of the adjusted inoculum suspension was added
to each well, resulting in the desired final drug concentra-
tion and inoculum size of 0.5 to 2.5 X 103 cells/ml. The
plates were incubated at 35oC for 48 h. A quality control
strain (C. parapsilosis ATCC 22019) was included on each
day of the assay to check the accuracy of the drug dilu-
tions and the reproducibility of the results.
The minimal inhibitory concentration (MIC) of the
azoles was defined as the lowest drug concentration which
resulted in a prominent decrease in turbidity, as compared
with that in the growth control (drug-free) well (NCCLS
1997).
Breakpoint definitions for fluconazole and itraconazole
MICs were recently proposed by the NCCLS M27-A stan-
dard guidelines, considering isolates with MICs ≤ 8 mg/
ml for fluconazole and ≤ 0.125 mg/ml for itraconazole as
susceptible, isolates with MICs between 16 and 32 mg/ml
for fluconazole and between 0.25 and 0.5 µg/ml for
itraconazole as having dose-dependent susceptibility
(DDS), and isolates with MICs ≥ 64 mg/ml for fluconazole
and ≥ 1 mg/ml for itraconazole as resistant. Due to the lack
of consensual definitions of breakpoints for the MICs of
ketoconazole, arbitrary values were established based on
those suggested by previous publications: susceptible
for isolates with MICs ≤ 0.125 µg/ml, DDS for isolates
with MICs between 0.25 and 0.5 µg/ml and resistant for
isolates with MICs ≥ 1 mg/ml  (Rodriguez-Tudela et al.
1995, St-Germain et al. 1995, Maenza et al. 1996).
RESULTS
A total of 142 isolates were recovered from 130 Aids
patients with oral candidiasis enrolled in the present study.
It is important to note that 11 patients were harboring
more than one specie and/or C. albicans serotype in their
oral cavities, at the time they were sampled. The age of
the patients ranged from 18 to 65 years (median  = 34
years) and 94 of them were males (72%). CD4+ lympho-
cyte counts were obtained from 115 of 130 patients and
the values ranged from 0 to 454 cells/mm3, with a median
count of 42 cells/mm3. Only 10 subjects  had values higher
than 200 cells/mm3. Aids had been diagnosed from zero
to 60 months before sample collection according to data
obtained from 109 of 130 patients (median = 3 months;
mean = 7.4 months). Fifty percent of the patients were
enrolled in this study during their first episode of oral
candidiasis, 35% had less than five episodes and only
15% had five or more episodes. Forty-eight patients (37%)
were under HAART at the time of enrollment in the study.
C. albicans was the most frequently isolated species (91%)
and 70% of the strains belonged to serotype A. A total of
12(9%) non-albicans species were isolated, including C.
glabrata (5), C. tropicalis (4), C. parapsilosis (1), C. krusei
(1), and Trichosporon inkin (1). We detected the pres-
ence of 12 co-infection episodes (9%), 3 of them repre-
sented by both serotypes of C. albicans. Table I illus-
trates the MIC ranges, MIC50 and MIC90 of the three
antifungal drugs tested against isolates of C. albicans
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serotype A (90), C. albicans serotype B (40), C. glabrata
(5), C. tropicalis (4), and C. krusei (1). Both serotypes of
C. albicans exhibited the same profile of susceptibility
against azole drugs and C. albicans isolates were more
susceptible than non-albicans species. The rank of sus-
ceptibility was C. albicans > C. tropicalis > C. glabrata
> C. krusei. Fourteen of the 130 patients (11%) were har-
boring in their oral cavities Candida spp. isolates DDS or
resistant to one or more azole drugs (Table II). The DDS/
resistant azole isolates included 8 C. albicans and 6 non-
albicans species.
DISCUSSION
C. albicans is the most pathogenic species of the ge-
nus Candida and is consistently the most frequently caus-
ative agent of candidal infection in humans. In Aids pa-
tients with OPC, C. albicans is followed in frequency by
C. glabrata, C. tropicalis, C. krusei, C. parapsilosis and
other non-albicans species (Hazen 1995, Coleman et al.
1998).
This is the first Brazilian multicenter study addressing
C. albicans serotypes and antifungal susceptibility pro-
files (using the NCCLS methodology) of yeasts obtained
from Aids patients with oropharyngeal candidiasis. We
found a high prevalence of C. albicans recovered from
HIV-infected and Aids patients with OPC (91%). Non-
albicans species were isolated from 12 (9%) patients ei-
ther as the sole isolate (n = 3) or in addition to C. albicans
(n = 9), these being considered cases of co-infection. C.
glabrata was the most frequent non-albicans species
recovered in this series, followed by C. tropicalis, C.
parapsilosis, C. krusei, and T. inkin. Oropharyngeal can-
TABLE I
Susceptibility profile of Candida spp. isolates against three antifungal drugs
Drug Species (n) MICs range MIC50 MIC90(µg/ml) (µg/ml) (µg/ml)
Fluconazole C. albicans A (90) 0.03-≥64 0.25 0.5
C. albicans B (40) 0.125-8 0.25 0.5
C. glabrata (5) 4-8 4 8
C. tropicalis (4) 0.125-1 0.5 1
C. krusei (1) 32 _ _
Itraconazole C. albicans A (90) 0.015-0.5 0.03 0.06
C. albicans B (40) 0.007-0.25 0.015 0.06
C. glabrata (5) 0.06-1 0.5 1
C. tropicalis (4) 0.03-0.06 0.03 0.06
C. krusei (1) 0.5 _ _
Ketoconazole C. albicans A (90) 0.015-0.5 0.015 0.06
C. albicans B (40) 0.015-0.125 0.015 0.03
C. glabrata (5) 0.06-0.25 0.125 0.25
C. tropicalis (4) 0.015-0.125 0.03 0.125
C. krusei (1) 0.5 _ _
TABLE II
Isolates identified as dose dependent susceptibilidy/resistant to fluconazole, itraconazole and ketoconazole by the microdilution
method, and CD4 cell count for the source patient
       MIC
Code Species FLZ ITZ KTZ CD4 Serotype
Cells/mm3
CBA09A Candida albicans      0.25 0.25 0.03  60 A
J17-D1 C. albicans        0.25 0.25 0.03  14 A
CUB02A C. albicans  2 0.5 0.03  ND A
CUB04A C. albicans  2 0.5 0.06  38 A
CUB09A C. albicans  4 0.5 0.125    8 A
J45-D22 C. albicans  8 0.25 0.125  167 B
CSP04A C. albicans ≥64 0.25 0.5  ND A
CSP09A C. albicans ≥64  0.125 0.125  30 A
CNA03B C. glabrata  8 0.5 0.125  54 -
CNA08B C. glabrata  4 0.5 0.25  40 -
CRP02B C. glabrata  4 1 0.25     67,3 -
CRP08C C. glabrata  4 0.25 0.125  20 -
CNA12B C. krusei 32 0.5 0.5 107 -
CBA16A Trichosporon inkin  2 0.5 0.125  29 -
MIC: minimal inhibitory concentration; FLZ: fluconazole; ITZ: itraconazole; KTZ: ketoconazole; ND: not documented
256 Candida spp. from Aids Patients  Priscilla de Laet SantAna et al.
didiasis due to Candida species other than C. albicans is
relatively uncommon, although it does occur, especially
in HIV-infected individuals, those with Aids and other
immunocompromised patients submitted to protracted
antifungal therapy. In HIV-infected patients, non-albicans
species have been isolated from 15 to 20% of patients,
and they are represented mostly by C. tropicalis, C.
parapsilosis, C. krusei and C. glabrata (Barchiesi et al.
1993, Milan et al. 1998).
C. albicans may be antigenically divided into two ma-
jor serotypes on the basis of differences in surface anti-
gens defined as A and B, originally described by
Hanseclever and Mitchell (1961). Antigenic expression
on the surface of the C. albicans cell wall is a very dy-
namic process, which may reflect the ability of the micro-
organism to adapt to the host. The variability may be in-
fluenced by environmental and nutritional factors, as well
as by the strain origin (Barturen et al. 1995). As a conse-
quence, the variability of the incidence of OPC caused by
serotypes A and B may be related to geographic diver-
sity, antifungal selective pressure, underlying conditions,
host factors and even by differences in the methods em-
ployed for C. albicans serotyping (Brawner 1991,
Torssander et al. 1996). In the literature the distribution of
serotypes A and B of C. albicans varies widely in differ-
ent series. One of the reasons for this variability may be
the number of the individuals evaluated in each series. In
our study, 70% of the C. albicans isolates belonged to
serotype A. In agreement with the data reported here,
Pires et al. (1996) found a 70% frequency of serotype A
from the oral cavities of Brazilian HIV patients. Thus, in
Brazil, serotype A of C. albicans seems to occur at high
frequency, particularly in Aids and HIV-infected patients.
In contrast, in some studies performed in Europe and the
USA, the authors suggested that C. albicans serotype B
seems to be more prevalent. Velegraki (1995) observed a
70% frequency of C. albicans serotype B in 30 Aids pa-
tients with OPC in Greece. In the US, a 65% prevalence of
serotype B was detected in Aids patient (Brawner & Cut-
ler 1989). In Sweden, Torssander et al. (1996) observed
that, among homosexual men, the prevalence of serotype
B was 40% in HIV-infected patients and 39% in HIV-se-
ronegative patients, while in control subjects of hetero-
sexual non-HIV men, the prevalence was only 7.5%. In
Europe, nevertheless, HIV-seronegative populations seem
to have also a greater prevalence of serotype A
(McMullan-Vogel et al. 1999, Williams et al. 2000).
In agreement with other authors, we found that both
serotypes of C. albicans exhibited similar in vitro suscep-
tibility patterns to all azole drugs tested. However, it should
be noted that serotype B seems to be significantly more
resistant than serotype A to 5-fluorocytosine (Auger et
al. 1979, Quindos et al. 1995).
Twelve cases of co-infection (9%) were detected, in-
cluding three cases of isolation of both serotypes of C.
albicans. Up to 15% of Candida spp. mixed cultures from
oral cavities of HIV-infected patients has been described
by other authors and the species isolated in addition to
C. albicans did not seem to play an important role in the
pathogenesis (Beighton et al. 1995, Dronda et al. 1996).
However, the presence of two or more species in the same
patient may predispose to recurrent candidiasis, mainly
in the presence of species for which azole MICs are intrin-
sically high, like C. glabrata or C. krusei (Millon et al.
1994). Of note, episodes of co-infection were observed in
our study among patients with none or low exposure to
antifungal drugs, as well as a CD4 count lower than 107/
mm³. These data suggest that co-infections may reflect
not only previous exposure to antifungal drugs, but also
the severity of the immunosuppression condition of pa-
tients and contact with patients harboring different spe-
cies.
Fourteen of the 130 patients (11%) harbored DDS yeast
isolates or isolates resistant to one or more azole drugs in
their oral cavities. Eight DDS or resistant isolates were C.
albicans and 6 were non-albicans species represented
by C. glabrata (4) and C. krusei (1) and T. inkin (1) iso-
lates. All non-albicans species mentioned are usually less
susceptible or resistant to azoles. Among the 8 C. albicans
isolates for which azole MICs were high, 2 isolates were
resistant to fluconazole and 6 were DDS to itraconazole.
Both resistant C. albicans isolates were found among
patients with previous exposure to antifungal drugs and
a CD4 count lower than 30 cells/mm³. The risk of develop-
ing mucosal candidiasis with reduced susceptibility to
azoles has been associated with greater duration of HIV-
infection, severe immunosuppression states and cumula-
tive prior exposure to antifungal drugs, mainly fluconazole.
Of note, 11 of 13 patients harboring DDS and/or resis-
tant Candida spp. isolates to azoles had CD4 count lower
than 67cells/mm³, and most of them reported a history of
recurrent OPC episodes and previous use of antifungal
drugs. Both C. albicans isolates, resistant to fluconazole
were obtained from patients (CSP04 and CSP09) who had
a long history of exposure to azoles, due to recurrent epi-
sodes of OPC (more than five episodes).
In conclusion, Brazilian Aids patients are infected
mainly by C. albicans serotype A, most of them suscep-
tible to all antifungal drugs. The occurrence of azole re-
fractory candidiasis and non-albicans species isolates
are more prevalent among patients in advanced stages of
disease, with a history of recurrent oral candidiasis and
exposed to intermittent or continuous antifungal therapy.
Thus, identification procedures up to the species level,
as well as antifungal susceptibility testing should be re-
quested mainly for Aids patients with OPC who exhibit
such conditions.
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